Dapagliflozin Tetraacetate NEW

‌Dapagliflozin Tetraacetate | SGLT2 Inhibitor Intermediate‌ 🌟
High-Purity Pharmaceutical API for Diabetes Drug Synthesis

📌 ‌Product Overview‌

Dapagliflozin Tetraacetate is a critical intermediate in the synthesis of ‌dapagliflozin‌, a leading SGLT2 inhibitor used globally to treat type 2 diabetes by regulating blood glucose levels‌13. It serves as a high-purity active pharmaceutical ingredient (API) for formulating oral antidiabetic medications and advanced pharmaceutical intermediates‌23.

‌Key Applications‌:

• Diabetes drug manufacturing 💊

• Pharmaceutical R&D laboratories 🔬

• Bulk API production for metabolic therapies 🧪

✅ ‌Key Advantages‌

🌍 ‌Applications‌

1. ‌Diabetes Therapeutics‌

   : Core intermediate for dapagliflozin API synthesis‌34.

2. ‌Pharmaceutical Research‌

   : Used in preclinical studies for novel SGLT2 inhibitors‌12.

3. ‌API Manufacturing‌

   : Integrated into GMP-compliant production lines‌23.

📜 ‌Quality Certifications‌

• Manufactured under ‌GMP‌ and ‌ISO 9001‌ guidelines‌.

• Tested via ‌HPLC, GC-MS‌, and residual solvent analysis‌.

• Full ‌COA‌ (Certificate of Analysis) provided per batch‌.

📈 ‌Market Trends‌

The global SGLT2 inhibitor market is projected to grow at ‌8.2% CAGR (2025-2030)‌, driven by rising diabetes prevalence and demand for precision therapies‌13. Dapagliflozin remains a top-tier drug, with API intermediates like Dapagliflozin Tetraacetate seeing ‌15% annual demand growth‌‌34.